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Complement Receptor Type 1 (CR1, CD35)
Is a Receptor for C1q
Lloyd B. Klickstein,*² Sergei F. Barbashov,³ of C1 is tightly regulated by the C1 inhibitor, which cova-
lently binds to the activated enzymatic subunits of C1,Tun Liu,³‖ Richard M. Jack,§
C1r, and C1s and removes them from C1q. C1q, stilland Anne Nicholson-Weller*³
bound to its immune complex or activating substance*Department of Medicine
via its globular domains, is now free to interact withHarvard Medical School
cells bearing receptors for its collagen-like domain. The²The Division of Rheumatology/Immunology
collagen-like domain, or collagen tail, is what remainsDepartment of Medicine
of the C1q molecule after the six globular domains areBrigham and Women's Hospital
digested away by pepsin (Reid, 1976). The collagen tail³Charles A. Dana Research Institute
consists of the six ªstemsº of C1q, which come togetherHarvard-Thorndike Laboratory
in the amino half of the constituent chains to form aDivision of Infectious Disease
single ªstalk.ºBeth Israel-Deaconess Medical Center
Receptors for aggregated or insolubilized C1q wereBoston, Massachusetts 02215
first recognized on lymphocytes (Dickler et al., 1972).§La Jolla Pharmaceutical
Subsequent studies identified monocytes, some PMN,San Diego, California 92121
and B lymphocytes as the predominant C1q binding cell
types in the peripheral blood (Tenner et al., 1981a). The
molecular definition of the C1q receptor(s) has been
Summary difficult, which may be explained in part by different
methods used to define different receptors on different
Molecular definition of the cellular receptor for the cell types. Using C1q affinity, Reid and coworkers identi-
collagen domain of C1q has been elusive. We now re- fied a 60 kDa protein (Malhotra et al., 1988, 1989) that
port that C1q binds specifically to human CR1 (CD35), is highly homologous, if not identical, to calreticulin (Mal-
the leukocyte C3b/C4b receptor, and the receptor on hotra et al., 1992; Stuart et al., 1996).
erythrocytes for opsonized immune complexes. Bio- Initially using a purification procedure also based on
tinylated or radioiodinated C1q (*C1q) bound specifi- C1q affinity, Ghebrehiwet and coworkers have described
cally to transfected K562 cells expressing cell surface different forms of membrane-binding C1q molecules
CR1 and to immobilized recombinant soluble CR1 ranging from 1±2 3 106 Mr (normal B lymphocytes) (Ghe-
(rsCR1). *C1q binding to rsCR1 was completely inhib- brehiwet et al., 1982) to 70±80k Mr (Raji cells) (Ghebrehi-
ited by unlabeled C1q and the collagen domain of C1q wet et al., 1984; Ghebrehiwet, 1988). The Raji cell C1qR
and was partially inhibited by C3b dimers. Kinetic an- had a domain with significant homology to a5/b1 and
alysis in physiologic saline of the interaction of un- the vitronectin receptor, av/b3 integrin (Ghebrehiwet et
al., 1992). More recently, this group has used antibodieslabeled C1q with immobilized rsCR1 using surface
against the 60k Mr C1qR (Ghebrehiwet, 1988; Malhotraplasmon resonance yielded an apparent equilibrium
and Sim, 1989) and identified calreticulin on surface-dissociation constant (Keq2) of 3.9 nM. Thus, CR1 is a
labeled endothelial cells (Peerschke et al., 1993) and thecellular C1q receptor that recognizes all three comple-
T cell line MOLT4 (Chen et al., 1994).ment opsonins, namely, C1q, C3b, and C4b.
Tenner and coworkers investigated the phagocytosis-
enhancing and superoxide-enhancing effects of C1q onIntroduction
monocytes and granulocytes. They used a C1q affinity-
purified fraction from U937 cells as an immunogen forComplement C1q is the 462 kDa recognition subunit
making MAbs and then selected several MAbs thatof multimeric C1, which when bound to a complement
blocked C1q-enhanced phagocytosis by monocytesactivating surface, causes the sequential activation of
and found that the MAbs reacted with a 126k Mr surfacethe enzymatic subunits of C1, C1r, and C1s. C1q avidly
protein (Guan et al., 1991). Using degenerate probesbinds IgG and IgM in immune complexes and thereby
based on amino acid sequence, they have identified aªcomplementsº acquired immunity by recruiting the
cDNA clone that directs expression of a protein with a
classical complement pathway. In addition, C1q can
predicted amino-terminal C-type lectin domain, five
directly bind DNA (Uwatoko et al., 1990), complexes of
EGF-like repeats, a single transmembrane domain, and
C-reactive protein (Jiang et al., 1991), serum amyloid P a short cytoplasmic tail (Nepomuceno et al., 1997). The
(Ying et al., 1993), isolated myelin (Vanguri et al., 1982), 126k Mr protein is expressed on both monocytes and
and urate crystals (Terkeltaub et al., 1983), as well as neutrophils (Guan et al., 1991).
some gram-negative (Tenner et al., 1984) and gram- Results from our laboratory indicated that the regula-
positive bacteria (Baker et al., 1982). By directly binding tion of C1q binding on human PMN was similar to the
foreign or abnormally expressed host molecules and regulation of complement receptor type 1 (CR1) and type
activating the classical pathway, C1q functions as part 3 (CR3) expression. Biotinylated C1q (C1qbio) binding
of the innate immune system. Whether activated by the and CR1 and CR3 expression were simultaneously up-
acquired or innate immune system, thecatalytic function regulated by FMLP, and microtubule stabilization with
taxol inhibited the up-regulation of C1qbio binding and
CR1 and CR3 expression (Jack et al., 1994). These find-‖ Present Address: Department of Biostatistics, School of Public
Health, University of Michigan, Ann Arbor, Michigan 48109. ings suggested to us that the C1q receptor of PMN
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Figure 1. Analysis of CR1-Transfected K562
Cells
(A) FACS analysis of CR1 expression on
transfected cells. Samples of cells trans-
fected with the control plasmid pHyg (left
panels) or the plasmid containing the cDNA
encoding CR1 (right panels) were incubated
with class-specific control MAb then FITC-goat
anti-mouse IgG (upper panels), or anti-CR1
(YZ-1), followed by FITC-goat anti-mouse IgG
(lower panels). The cells were subsequently
fixed and analyzed by FACS. The K-Hyg cells
(lower left) showed no positive staining for
CR1, while the K-CR1 cells (lower right) dis-
played a broad histogram of positive staining.
(B) Western blot analysis of NP-40 cell lysates
of K-Hyg and K-CR1 cells using rabbit anti-
CR1 and iodinated protein A as a probe. The
K-CR1 cells have a unique 200k Mr band cor-
responding to intact CR1.
(C) Adherence of transfected K562 cells.
K-CR1, but not K-Hyg, bound to C3b immobi-
lized on plastic. Adherent cells were counted
by microscopy.
(D) SDS±PAGE analysis under reducing con-
ditions of purified proteins (4 mg/lane) on a
4%±20% slab gel.
either was in the same intracellular storage vesicle as the K-CR1 cells were selected for cell surface expres-
sion of CR1 by panning but the cells were not cloned,CR1 and CR3 or was identical to CR1 or CR3. The cata-
lytic subunits of C1, C1r, and C1s, which bind C1q a heterogeneous expression of CR1 was expected. The
recombinant CR1 molecule was shown to be intact by(Lepow et al., 1963), have complement short consensus
repeat (SCR) motifs (Journet et al., 1986; Leytus et al., immunoprecipitation and Western blot analysis using
polyclonal anti-CR1 (Yoon et al., 1985) and iodinated1986; Tosi et al., 1987) and therefore share homology
with CR1, which has 30 SCR in its extracellular domain protein A as a probe (Figure 1B). The K-CR1 bound to
C3b immobilized on plastic, while K-Hyg did not bind(Klickstein et al., 1987). Thus, it was logical to assess if
C1q could bind CR1. (Figure 1C). SDS±PAGE analysis of the purified proteins
used in the experiments confirms their purity and ex-In this paper, we provide evidence, from two different
equilibrium binding assays and a kinetic binding assay, pected molecular structures (Figure 1C).
that C1q can indeed bind CR1. C1q has at least two
binding sites for CR1, presumably involving some of its Measurement of C1q Binding to Transfected Cells
six identical stems, where C1r and C1s also bind (Siegel Transfected cells were incubated at 378C for 30 min with
et al., 1983). These results indicate that CR1, the recep- increasing amounts of biotinylated C1q (C1qbio) in Ca11-
tor normally responsible for binding immune complexes and Mg11-free low ionic strength buffer, HBSS/2. Cells
and mediating their transport to the liver and spleen for were subsequently incubated with FITC-avidin and ana-
clearance, can bind to any of the complement fragments lyzed by FACS. A plot of the mean fluorescent channel
that mark immune complexes for clearance, namely (MFC) versus C1qbio input indicated specific binding of
C1q, C3b, and C4b. C1qbio (Figure 2A). The binding was saturable and half
maximal binding was seen at a C1qbio concentration of
Results
7.6 3 1028 M. The C1q binding assay was repeated
using 125I-C1q. K-Hyg and K-CR1 cells were incubated
Characterization of Transfected Cells with increasing amounts of 125I-C1q for 45 min at room
The human erythroleukemia cell line K562 was trans- temperature. A dose-dependent increase in 125I-C1q
fected with the plasmid paABCD, which directs the ex-
binding was observed (Figure 2B). However, it was not
pression of the F allotype of human CR1, together with
technically possible to reach saturation because the
the plasmid pBSHyg, which directs resistance to the
iodinated C1q aggregated at higher concentrations. A
antibiotic hygromycin (K-CR1), or with pBSHyg alone
50-fold excess of unlabeled C1q inhibited 82% (mean,
(K-Hyg). The K-CR1 and the control K-Hyg transfectants
n 5 3) of 2.6 nM 125I-C1q binding.
were characterized for CR1 expression using control
MAb and the anti-CR1 MAb YZ-1. There was no YZ-1
C1q Binding to CR1 Immobilized to Microtiter Wellsstaining of the K-Hyg cells, compared with a control
To circumvent the problem of background C1q bindingMAb (MFC of FITC-second antibody alone 5 9.25; MFC
to other cell surface sites, a recombinant, soluble con-of anti-CR1 plus FITC-second antibody 5 8.69) (Figure
struct of the entire extracellular domain of CR1 (rsCR1)1A, left panels). In the same analysis, K-CR1 demon-
was immobilized in microtiter wells. Preliminary titrationstrated a heterogenous pattern of positive staining com-
pared with its control (Figure 1A, right panels). Because of rsCR1 binding to the plate indicated that 0.5±0.8 mg
CR1 (CD35) Is a Receptor for C1q
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Figure 3. Effect of Ionic Strength on C1qbio Binding to Insolubilized
rsCR1
Recombinant sCR1 (5 mg/ml) was used to coat microtiter wells. After
washing and blocking, C1qbio (0.5 mg/well), diluted in the respective
ionic strength buffer, was added for a 30 min incubation at room
temperature. The wells were washed 23 with the respective buffer.
Results represent the mean of duplicate values,while the bars depict
the range of values. This experiment was repeated with a similar
inverse relationship between ionic strength and C1qbio binding.
native C1q (Figure 4B). A concentration of 0.4 nM unla-
beled C1q inhibited 125I-C1q binding by 50%. The colla-
Figure 2. Labeled C1q Binding to Transfected Cells gen ªtailº portion of C1q, which was obtained by pepsin
(A) C1qbio Binding. After blocking nonspecific avidin and biotin bind- digestion of C1q,also competed with 125I-C1q for binding
ing sites, samples of K-Hyg and K-CR1 (5 3 106 cells) were reacted to immobilized rsCR1, which indicated that CR1 binds
with increasing concentrations of C1qbio for 30 min at 378C in low to the same collagen domain of the C1q molecule as
ionic strength buffer (HBSS/2; see Experimental Procedures for de-
does C1r and C1s (Siegel and Schumaker, 1983). Intails). The cells were subsequently reacted with FITC-avidin, fixed
two experiments, 50% inhibition of 125I-C1q binding wasin 1% paraformaldehyde, and analyzed by FACS. The mean fluores-
observed with about 10±15 nM of the collagen tails (datacent channel (MFC) of the single dominant peak was determined
based on analyzing 20,000 cells. This experiment was repeated two not shown). (C3b)2 also inhibited 125I-C1q for binding to
other times with similar net positive binding of C1qbio to K-CR1 cells CR1, but less efficiently than C1q (Figure 4C). Because
as compared with K-Hyg. (C3b)2 is a well-described ligand for CR1 (Fearon, 1980),(B) 125I-C1q binding. Transfected K-Hyg and K-CR1 cells, each at
this affords additional specificity to the competition5 3 106/ml, were incubated with increasing doses of 125I-C1q (spe-
assays.cific activity: 1.1 3 106/mg), diluted in low ionic strength buffer
(HBSS/2). After a 45 min incubation at room temperature, three
replicate 0.1 ml samples were removed from each reaction mixture,
Kinetic Measurement of C3b or C1qlayered onto oil, and centrifuged to pellet the cells. The cell pellet
Binding to rsCR1containing 5 3 105 cells was cut off and counted. The means of
triplicate values 6 SE are depicted. At the highest input of 125I-C1q To demonstrate that C1q could bind CR1 under physio-
(2.6 nM), a 50-fold excess of unlabeled ligand inhibited specific logic conditions and to avoid the deleterious effects
binding by 82% (*). This experiment was repeated four times with of labeling procedures on the activity of C1q, surface
similar results.
plasmon resonance analysis of binding was performed
using a BIAcore instrument. This technique measures
in real time the association and dissociation of unlabeledof rsCR1/well provided optimal C1q binding. C1q bind-
ing to cells was facilitated by low ionic strength, but ligand to an immobilized receptor, or vice versa, by
changes in the adjacent refractive index (Cullen et al.,C1q also aggregated at low ionic strength, which can
make binding assays technically difficult. To identify an 1987). In a typical experiment, rsCR1 was covalently
coupled to a CM5 dextran chip and resulted in the netionic strength closest to normal for the plate assay that
would permit reproducible measurement of C1q binding addition of 9052 resonance units (RU) to the chip.
To confirm that the coupled rsCR1 was functionallyto immobilized rsCR1, we tested the ability of C1qbio to
bind under various ionic strength conditions. Adequate intact and to establish the validity of this method for
measuring thebinding of complement fragments toCR1,binding was measured in 0.1 M NaCl (Figure 3), thus
subsequent plate binding studies were done in an equiv- we assessed the ability of a known CR1 ligand, namely
soluble (C3b)2, to bind to the coupled rsCR1. Specificalent low ionic strength buffer (ª0.67 3 PBS-Tweenº 5
67% PBS, 33% dHOH, 0.05% Tween-20, 5.9 mSi at 08C). binding of (C3b)2 to rsCR1 was observed using five dif-
ferent concentrations of (C3b)2 ranging from 8.3 nM toThe specific binding of 125I-C1q to immobilized rsCR1
is shown in Figure 4A. Half maximal binding was ob- 67 nM. Figure 5A illustrates the observed association
and dissociation of (C3b)2, which was used to deriveserved at 0.5 nM of 125I-C1q. The total binding observed
in this assay was approximately 30-fold lower than that the association and dissociation rate constants. The
association phase of the interaction was modeled asin the cell binding assay (Figure 2B) because of the
higher ionic strength used in the plate assay. Binding simple bimolecular binding, because the (C3b)2 ligand
was employed at a concentration 20- to 60-fold belowof labeled C1q to immobilized rsCR1 was inhibited by
Immunity
348
Figure 5. Kinetic Binding Data: C3b Dimers Bind to CR1, Document-
ing That Immobilized rsCR1 Is FunctionalFigure 4. Binding of 125I-C1q to Immobilized rsCR1 and Competition
by Unlabeled Ligands (A) Plot of resonance units (RU) versus time illustrating the observed
association and dissociation of (C3b)2. The association was moni-Recombinant sCR1 (8 mg/ml) was immobilized in microtiter wells,
tored from 0 to 300 sec, and the dissociation occurred during theand binding was performed in 0.67 3 PBS-Tween buffer in the
interval from 450 to 600 sec.absence of added Ca11 and Mg11, as described in the Experimental
(B) Data from (A) were used to plot Ks versus [(C3b)2]. The slope ofProcedures.
the least squares regression line (r2 5 0.977) corresponds to the(A) Direct 125I-C1q binding to plated rsCR1. Results are the means 6
apparent association rate constant.SE, n 5 4. This experiment was repeated with similar results.
(B) Competition of 125I-C1q binding by native C1q. 125I-C1q (0.87 nM)
binding to immobilized rsCR1 was measured in the presence of
increasing concentrations of unlabeled C1q in0.1 M buffer. Means 6 shown). Table 1 contains the observed rate constants,
SE, n 5 3 are plotted. This experiment was repeated with similar ka and kd, and the calculated equilibrium dissociationresults. Unlabeled C1q at 0.4 nM inhibited 125I-C1q binding by 50%.
constant, Keq, which corresponds to the ligand concen-(C) Competition of 125I-C1q binding by (C3b)2. 125I-C1q (0.87 nM) was
tration at which half of the receptors are occupied. Theadded to wells containing immobilized rsCR1 in the presence of
Keq for (C3b)2 binding to CR1 was calculated for the fiveincreasing amounts of (C3b)2. Results are the means 6 SE, n 5 4.
(C3b)2 concentrations used and averaged 27.6 nM, with
a range from 17.9 nM to 40.6 nM. An alternative analysis
of the association kinetics, which does not assume athe value of the reported equilibrium dissociation con-
stant (Keq) of monomeric C3b for CR1 (Arnaout et al., known kd, yielded a ka of 9.79 3 104 mol21 3 sec21, an
apparent kd of 1.7 3 1023 sec21, and a calculated Keq of1981). Further, the sequential binding of two identical
binding sites would not significantly change the ob- 17.4 nM (Figure 5B). Using the more reliable average kd2
determined from the dissociation kinetics, 2.078 x1023served association kinetics (Gertler et al., 1996). At the
time the dissociation phase begins, the (C3b)2 may be sec21 (Table 1), the calculated Keq for (C3b)2 binding to
CR1 is 21.2 nM, in good agreementwith the first method.bound monovalently or divalently; thus, a curve-fitting
model assuming parallel dissociation of two distinct These values are not significantly different from the pre-
vious determination of 9.5 nM for a similarly preparedcomplexes was employed. The association and dissoci-
ation models closely fit the experimental data (not (C3b)2 (Arnaout et al., 1981), thus validating ourmethods.
CR1 (CD35) Is a Receptor for C1q
349
Table 1. Kinetic Data for (C3b)2 Binding to Immobilized CR1
[C3b]2 nM ka (SE) 3 1024 mol21 3 sec21 kd1 (SE) 3 103 sec21 kd2 (SE) 3 103 sec21 Keq1 (SE) mM Keq2 (SE) nM
8.3 5.5 (1.8) 65.8 (15.8) 1.9 (0.9) 1.2 (0.49) 34 (19.8)
16.7 6.0 (0.9) 276 (11.1) 2.4 (0.04) 4.6 (0.71) 40 (6.0)
33.3 10.5 (0.3) 261 (14.2) 2.2 (0.05) 2.5 (0.15) 21 (0.77)
50.1 8.3 (0.2) 346 (46.6) 2.1 (0.05) 4.2 (0.57) 25 (0.85)
66.7 9.9 (0.2) 110 (17.7) 1.8 (0.4) 1.1 (0.18) 18 (4.0)
3Å 5 2.7 mM (1.06) 3Å 5 27.6 nM (21.1)
In a similar analysis using five different concentrations Using the latter dissociation constants in a simple asso-
ciation model, the apparent ka ranged from 2.86 3 105of unlabeled C1q ranging from 6.5 to 52.2 nM, binding
to CR1 was evident in normal ionic strength buffer (Fig- to 4.34 3 105 mol21 3 sec21 (Table 2). The calculated
Keq for the slowly dissociating C1q±CR1 complex aver-ure 6A). No C1q binding was observed to a parallel
channel that was not derivatized, or to a channel that aged 3.9 nM, with a range from 2.27 nM to 5.17 nM. An
alternative analysis of the association kinetics, whichwas derivatized with C1q, data that demonstrated the
specificity of C1q binding to rsCR1 in this assay. Using does not assume a known kd, yielded a ka of 4.34 3 105
mol21 3 sec21, an apparent kd of 1.95 3 1023 sec21, andthe same kinetic models as used for (C3b)2 binding, a
good fit to the experimental data was obtained. Analysis a calculated Keq of 4.49 nM (Figure 6B). Using the more
reliable average kd determined from the dissociationof the dissociation data for the more rapidly dissociating
complex yielded an apparent kd that ranged from 0.019 kinetics, 1.49 3 1023 sec21, the calculated Keq for C1q
binding to CR1 was 3.43 nM, in good agreement withto 0.033 sec21 among the five concentrations analyzed.
The more slowly dissociating complex had an apparent the first method. The most likely interpretation of these
data is that the slowly dissociating complex interactedkd that ranged from 0.84 3 1023 to 2.09 3 1023 sec21.
with CR1 via more of the six identical stems of C1q than
did the rapidly dissociating complex. Importantly, C1q
has a higher apparent affinity for CR1, under normal
ionic conditions, than does (C3b)2.
When C1q was directly immobilized to the chip by
NHS/EDC chemistry, we were unable to detect rsCR1
binding in isotonic buffer (data not shown). In retrospect,
this was probably because the C1q was denatured dur-
ing the coupling reaction, which has been observed with
other proteins (Gertler et al., 1996). However, when
C1qbio was immobilized to a streptavidin chip, it was
possible to detect CR1 binding, but only at relatively
high concentrations of rsCR1 (435 nM to 3480 nM). The
very rapid association and dissociation of rsCR1 to the
immobilized C1qbio precluded an accurate determination
of the rate constants by the BIAcore technique (BIA
Evaluation and BIA Simulation, Pharmacia). The most
likely explanation for why C1q bound at high apparent
affinity to immobilized CR1, while soluble CR1 bound
poorly to immobilized C1q, is that C1q has a higher
valency for CR1 than CR1 has for C1q. For example,
C1q with its six identical stems may have six binding
sites for CR1, while CR1 apparently has fewer sites for
binding to C1q.
Localization of a Binding Site in LHR-D for C1q
Using deletion mutations that previously had been em-
ployed to define the binding sites for C4b and C3b
(Klickstein et al., 1988), we found that 125I-C1q tails con-
sistently bound to a fragment of rCR1 containing the
Figure 6. Kinetic Binding Data: C1q Binds to Immobilized rsCR1 nine SCR closest to the membrane. This region includes
the fourth LHR, LHR-D (SCR 22±28) (Figure 7). Because(A) Plot of resonance units (RU) versus time illustrating the observed
association and dissociation of C1q in normal saline. The associa- all of the constructs studied contained all or part of
tion was monitored from 0 to 120 sec, and the dissociation occurred LHR-D, we could not exclude additional binding sites in
during the interval from 120 to 250 sec. LHR-A, -B, or -C. Computer-aided sequence alignment
(B) Data from (A) were used to plot Ks versus [C1q]. The slope of
(Wisconsin Package, Version 8, Sept. 1994, Geneticsthe least squares regression line (r2 5 0.947) corresponds to the
Computer Group, 575 Science Drive, Madison, WIapparent association constant, determined without assuming
knowledge of the dissociation rate constant. 53711) revealed that the SCR in C1r and C1s are most
Immunity
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Table 2. Kinetic Data for C1q Binding to Immobilized CR1
ka (SE) 3 1025
[C1q] nM mol21 3 sec21 kd1 (SE) 3 103 sec21 kd2 (SE) 3 103 sec21 Keq1 (SE) nM Keq2 (SE) nM
6.5 3.7 (2.63) 23.6 (4.8) 0.84 (0.03) 64 (47.3) 2.3 (1.64)
13.0 2.7 (1.08) 22.3 (3.4) 1.24 (0.04) 83 (35.5) 4.3 (1.73)
26.0 4.3 (0.57) 23.7 (1.5) 1.54 (0.03) 55 (8.1) 3.6 (0.48)
39.0 4.3 (0.13) 19.1 (1.1) 1.74 (0.06) 44 (2.9) 4.0 (0.18)
52.0 4.0 (0.285) 32.7 (1.9) 2.09 (0.04) 82 (7.5) 5.2 (0.38)
3Å 5 59 nM (60.2) 3Å 5 3.9 nM (2.47)
homologous to SCR of LHR-D, which is consistent with sites on CR1, we consistently detected good binding
of 125I-collagen tails to a construct containing LHR-DLHR-D containing a CR1 binding domain for C1q.
(SCR-22±28) and the last two SCR of the extracellular
domain, SCR 29 and 30. Interestingly, the region of CR1Discussion
most homologous to the SCR of C1r and C1s is LHR-D.
Until now, there has been no binding function assignedCR1 (CD35) is a single-chain, integral membrane glyco-
to this region.protein that has been recognized as the major cellular
The (C3b)2 partially inhibited binding of C1q to immobi-receptor for C4b and C3b (Fearon, 1980). The extracellu-
lized CR1. One possible explanation for thepartial inhibi-lar domain of the protein is comprised of SCR, which
tion is that the binding sites for the two ligands differ,are characteristic of C3/C4 binding proteins (reviewed
but are close enough that (C3b)2 sterically hinders C1qin Hourcade et al., 1989). The rsCR1 used in these stud-
binding. Both (C3b)2 and C1q are large molecules,ies is truncated after SCR 30. Groups of 7 SCRs in CR1
≈360,000 and 462,000 daltons, respectively. A secondare further organized into 4 long homologous repeats
possibility is that there is more than one binding site for(LHR-A, -B, -C, and -D) (Klickstein et al., 1987). LHR-A
C1q that accounts for the partial inhibition of C1q bind-contains a C4b binding site, and LHR-B and LHR-C each
ing by (C3b)2. This would be consistent with our suspi-contain a binding site for C3b (Klickstein et al., 1988;
cion that there is an additional binding site for C1q out-Krych et al., 1991), which also binds C4b, but at a lower
side of LHR-D (data not shown). Thirdly, the binding ofaffinity (Reilly et al., 1994). We have demonstrated C1q
(C3b)2 may affect the tertiary structure of CR1 in a waybinding to CR1 by three different means: (1) equilibrium
that inhibits C1q binding. These three possibilities arebinding of labeled C1q to CR1-transfected K562 cells
not mutually exclusive.(Figures 2A and 2B); (2) equilibrium binding of labeled
Derivatization of ligands always risks introducing arti-C1q (Figures 3 and 4) and labeled C1q tails (Figure 7)
facts, and C1q is especially sensitive to manipulation.to plated rsCR1; and (3) real-time binding of unlabeled
It was reported recently that C1qbio, along with otherC1q to immobilized rsCR1 in normal saline (Figures 6A
biotinylated proteins, failed to show any specific bindingand 6B). Although there are likely other C1q binding
to cells (Storm et al., 1996). We have found that in the
case of C1q, its specific binding to PMN (Jack et al.,
1994), CR1-transfected cells, and to plated CR1, and its
residualhemolytic activity areadversely affected by high
levels of biotinylation. However, with low levels of bio-
tinylation, and also helped by the use of avidin/biotin
blocking reagents (Vector Labs), C1qbio demonstrates
specific binding to K-CR1 (Figure 2A). During the course
of these experiments, we found that the hemolytic func-
tion of C1q was more sensitive to biotinylation than the
binding site for CR1. Biotinylating with NHS-biotin at 0.6
mg/ml and 30 mg/ml yielded two preparations of C1qbio
with near normal binding to CR1, but with 23% and 90%
losses in hemolytic activity, respectively. Radiolabeling
C1q has also been shown to increase the dissociation
constant of C1r and C1s from C1q (Tseng et al., 1997).Figure 7. Binding of 125I-C1q Collagen Tails to Immobilized Con-
In our plate binding assay performed at 2/3 normal ionicstructs of CR1
strength (5.9 mSi), the 1/2 maximal binding of C1q (Fig-Microtiter wells were coated with anti-LHR-D (MAb 6B1, T Cell Sci-
ure 4A) and 1/2 maximal inhibition by unlabeled C1qences) at 3 mg/ml and blocked with milk. NP-40 lysates of equal
(Figure 4B) were about 0.5 nM. Surface plasmon reso-numbers of control, and transfected CHO cells were added to allow
the MAb to capture the constructs. Lysates of nontransfected CHO nance analysis, on the other hand, allowed the direct
cells were added to some wells to allow determination of nonspecific measurement of binding by nonderivatized C1q in nor-
binding. After washing wells, 125I-C1q collagen tails (10 nM) were mal ionic strength buffer. The affinity values derived
added for binding in 0.67 3 PBS-Tween binding buffer (5.9 mSi).
from the two methods are internally consistent, consid-Results (mean 6 SE, n 5 4) are the specific binding, which has been
ering that C1q would be expected to have a lower bind-normalized to equal molar amounts of constructs (see Experimental
ing affinity in the plasmon resonance analysis becauseProcedures). This experiment was repeated using binding buffers
of 3.75, 4.44, and 5.9 mSi with similar results. of the adverse effect of a higher salt concentration on
CR1 (CD35) Is a Receptor for C1q
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binding to rsCR1 (Figure 3). It is interesting to note that known about how CR1 might mediate transmembrane
signaling. CR1 participation in the cellular responses toboth C1r2C1s2 binding and CR1 binding to C1q occur in
C1q might require that other molecules be recruited.the collagen domain (Figure 7) and both binding reac-
There is precedence for CR1 associating with other mol-tions are strongly inhibited by salt (Siegel and Schu-
ecules: CR1 is known to associate with CD21 in themaker, 1983; Tseng et al., 1997). CR1, C1r, and C1s all
membrane of B cells (Tuveson et al., 1991; Matsumotocontain SCR units; therefore, we propose that there is
et al., 1993), and when CR1 is cross-linked, it formsa common binding site on the collagen stems of C1q
attachments to the cytoskeleton (Jack et al., 1986;for SCR-containing proteins. This hypothesis is sup-
Brown, 1989). Finally, CR1 may not be the only C1qported by the observation that when C1r2C1s2 is bound
receptor, since C1q reportedly does bind and activateto C1q, the C1q is unable to bind to C1qR-bearing cells
some cells, e.g., endothelial cells (Zhang et al., 1986;(Tenner et al., 1980).
Lozada et al., 1995), which do not express detectableAn intriguing question is why CR1 was not identified
CR1 (Shaw et al., 1995).as a C1q receptor previously. While this may have to
There are important biological implications for C1q/do with the low density of CR1 expression on resting
CR1 binding. CR1 on erythrocytes is critical for the trans-cells (Arnaout et al., 1981; Fearon et al., 1983), the most
port of immune complexes and their subsequent clear-likely explanation is that insolubilized C1q is a poor affin-
ance. Thus, CR1 in humans may be solely responsibleity ligand for CR1. If the Keq for CR1 binding to immobi-
for clearing immune complexes opsonized by comple-lized C1q were in the range of 0.3±3 mM, where binding
ment, whether C1q and/or C3b/C4b. That C1q mightwas observed to immobilized C1qbio in the BIAcore anal-
participate in the clearance of immune complexes mayysis (data not shown), then the CR1 concentration in
explain several clinical observations. It is well recog-cell lysates would be far too low to detect specific bind-
nized that deficiencyof an early component of theclassi-ing. The presence of detergent used to solubilize cell
cal pathway predisposes to autoimmune diseases, typi-membranes might further impair binding. The probable
cally SLE (Lachmann, 1984; Atkinson, 1986). Only aboutexplanation for why CR1 binds poorly to immobilized
half of the patients with homozygous C2 deficiency have
C1q, while C1q binds at high apparent affinity to immobi-
lupus-like disease characterized primarily by cutaneous
lized CR1, is that C1q has a higher valency for CR1 than
manifestations, and vital organ involvement is uncom-
CR1 has for C1q. For example, C1q with its six identical
mon (Colten et al., 1992). In contrast, C1q deficiency is
stems may have six binding sites for CR1, while CR1 almost invariably associated with SLE (31/33 patients)
has fewer sites for binding to C1q. Consistent with this (Petry et al., 1997), and the disease is very severe, often
hypothesis, CR1 on the surface of cells is highly clus- including central nervous system pathology, glomerulo-
tered (Petty et al., 1980; Edberg et al., 1987; Paccaud nephritis, and the presence of autoantibodies (Bowness
et al., 1988, 1990; Chevalier et al., 1989), which would et al., 1994). The clinical manifestations of homozygous
allow one molecule of C1q to interact with multiple CR1 C4 deficiency are intermediate in severity between those
molecules. associated with C2 and C1q deficiency (Colten and Ro-
The role of CR1 with respect to other molecules pro- sen, 1992). Deficiency of C2 would result in defective
posed as C1q receptor will have to bedefined. Calreticu- opsonization by C3 only, while deficiency of C4 would
lin has been proposed as a C1q receptor, but it is primar- result in defective opsonization by both C4 and C3.
ily found in the ER, where it acts as a Ca11-binding However, immune complexes might still be effectively
protein and as a chaperonin for nascent proteins. Per- opsonized by C1q. In C1q deficiency, however, neither
haps as a consequence of this chaperone function, cal- C1q, C3b, nor C4b would effectively bind to immune
reticulin is also found in the granule fraction of some complexes, and the complexes might then be deposited
cells (reviewed in Bleackley et al., 1995) and might be in vital organs such as the kidney rather than the normal
expressed on cells as a consequence of degranulation targeting to liver and spleen for clearance (reviewed in
and the adsorption to plasma membrane (Eggleton et Hebert, 1991). An alternate hypothesis places the critical
al., 1994). It is unclear how such adsorbed calreticulin role of C1q in preventing autoimmune disease before the
could act as a receptor. Recent work indicates that cal- formation of immune complexes. In a recently published
study, C1q has been shown to directly bind to the blebsreticulin preferentially binds to the globular domain, as
of apoptotic keratinocytes (Korb et al., 1997). Becauseopposed to the collagen domain of C1q (Kishore et al.,
these blebs are enriched in nuclear antigens recognized1997). These data have not been reconciled with the puta-
by autoantibodies in SLE, it is hypothesized that C1q istive role of calreticulin as the C1q receptor for the colla-
normally involved in the clearance/tolerance of thesegen domain. Antibodies to a recently cloned 126k Mr
antigens.transmembrane protein block the C1q-stimulated phago-
The mechanism underlying the severe autoimmunecytosis by monocytes (Guan et al., 1991; Nepomuceno
disease associated with C1q deficiency may be due toet al., 1997). No binding of C1q has been demonstrated
the inability to activate the classical pathway or theto this novel 126k Mr protein; thus, it may participate as
inability to recruit C1q receptor±bearing cells. Now thatan element of a larger C1q receptor complex. If the
CR1 has been identified as a C1q receptor, it will beamino-terminal C-type lectin domain of this transmem-
possible to address these alternatives.brane protein were responsible for binding C1q, one
would expect that C1q binding to cells would be Ca11-
Experimental Proceduresdependent, which was not observed (Jack et al., 1994).
Although C1q has many biological effects presumably Buffers/Reagents
mediated through cell surface receptors, (reviewed in PBS used in microtiter well assays: 0.15 M NaCl, 0.05 M sodium/
potassium phosphate (pH 7.4). PBS used in plasmon resonanceGhebrehiwet et al., 1993; Tenner, 1993), there is little
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assays: 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4 experiment by combining the beads in different ratios and measur-
ing the resultant enzymatic activity using 0.1% D-glucose in tetra-(pH 7.3). The C1q binding buffer used with transfected cells was
methylbenzidine solution (Kirkegaard and Perry, Gaithersburg, MD)ªHBSS/2º 5 1 vol HBSS without Ca11/Mg11:1 vol 5% glucose-0.2%
as the substrates. The development of blue color was followedgelatin solution). The C1q binding buffer used in the microtiter plate
spectrophotometrically.assay was 0.67 3 PBS-Tween 5 67% PBS, 33% dHOH, 0.05%
At the time of radiolabeling, glucose oxidase beads (3 ml of aTween-20, 5.9 mSi at 08C). The following reagents were purchased
slurry) and lactoperoxidase beads (12 ml of a slurry) were washedas noted: 1,3 diaminopropane (Sigma Chemical, St. Louis, MO),
into PBS. Sodium-125Iodine (3 ml, carrier free, 100 mCi/ml, New En-dinonyl phthalate (Arcos, Geel, Belgium), dibutyl phthalate (Sigma).
gland Nuclear, Boston, MA) was added to the bead pellet, followedRecombinant soluble human CR1 (rsCR1) was kindly provided by
by 70 ml of C1q (400 mg/ml in 2 3 PBS), 70 ml of dHOH, and 10 mlDrs. Una Ryan and Henry Marsh of T-Cell Sciences, Needham, MA.
of glucose solution (100 mg/ml PBS). The reaction proceeded for
20 min at room temperature with intermittent shaking. The reactionComplement C1q and Collagen Tails of C1q
supernatant was applied to a PD-10 gel filtration column (Phar-C1q for biotinylation (as used in Figure 2A) was isolated from human
macia), which hadbeen equilibrated in PBS, 0.1% gelatin. The radio-serum by a procedure using BioRex 70, as originally described
labeled C1q was pooled and characterized. 98% of CPM of the 125I-(Tenner et al., 1981b) and modified (Jack et al., 1994). Each batch
C1q were precipitable with 10% TCA. 125I-C1q was quantified by aof C1qbio was tested for functional activity (Tenner et al., 1981b).
sandwich ELISA using anti-C1q MAb (Quidel, San Diego, CA) as the
Because of the propensity of the native C1q made by the BioRex
capture antibody and goat anti-human C1q (IncStar, Stillwater, MD)
method to aggregate, an alternative isolation method for C1q, utiliz- as the indicator antibody. The reaction was developed with horse-
ing fractional euglobulin precipitation and gel permeation chroma- radish peroxidase±conjugated rabbit anti-goat IgG (IncStar) and tet-
tography, was devised to prepare C1q for radiolabeling. In brief, 30 ramethylbenzidine substrate. The color reaction was stopped by
ml of fresh serum, 5 mM EDTA was dialyzed against a euglobulin the addition of H3PO4, and the OD450 was quantified using an ELISAprecipitation buffer (20 mM morpholine ethane sulfonic acid, 5 mM plate reader (Molecular Devices, Menlo Park, CA). C1q of a known
benzamidine, 0.5 mM EDTA [pH 6.5]) in tubing for 16 hours at 48C. protein concentration was used as a standard. Multiple lots of C1q
The precipitate was collected by centrifugation (8000 3 g, 10 min), were iodinated with specific activity ranging from 5 3 105±1 3 106
washed twice in 5 mM propanediamine, 0.05 mM EDTA (pH 8.8) CPM per mg of C1q as quantified by ELISA, and the functional
(PDE buffer) (Liberti et al., 1981), then dissolved in 1.4 ml of PDE activity was 400 hemolytic units (Z) per mg.
buffer supplemented with 300 mM NaCl (PDE/NaCl), 0.5 mM PMSF. Collagen tails of C1q were radioiodinated using IodoGen (Pierce
The mixture was centrifuged at 10,000 3 g for 5 min to remove Chemicals, Rockville, IL) to a specific activity of 2.4 3 105 cpm/mg
undissolved precipitate. The supernatant containing C1q was ali- of protein.
quoted (0.45 ml) to each of three microfuge tubes. Cold water (1
ml) was added to each tube, and after 10 min at 48C, the resulting Preparation of (C3b)2
precipitates were collected by centrifugation (10,000 3 g, 5 min). C3 purified from fresh human plasma by standard methods (Ham-
The precipitates in each tube were dissolved in 75 ml of PDE/NaCl mer, 1981, #248) was treated with trypsin to produce C3b (Fearon,
buffer, and then 85 ml of 2 3 PBS was added. This material was 1983, #638). The trypsin was inactivated by addition of diisopropyl-
recentrifuged (15,000 3 g, 5 min), and 150 ml was applied to a TSK fluorophosphate and the C3b purified by chromatography on Sepha-
G4000SWXL column (Supelco, Bellefonte, PA) equilibrated in 2 3 crylS300 in PBS. The fractionscontaining C3b were pooled, concen-
PBS, 0.5 mM EDTA at a flow rate of 0.5 ml per min. C1q eluted as trated to 1.4 mg/ml (Centriprep, Amicon, Beverly, MA), and stored
a peak with a retention time of 18.6 min consistent with a MW of at 48C for 3 weeks to allow formation of dimers via oxidation of the
462 kDa), and the peak was collected by hand. Analysis of the C1q free sulfhydryl group, as occurs in stored C3 (Arnaout et al., 1981).
revealed the distinct a, b, and c chains by SDS±PAGE with silver (C3b)2 was separated from monomeric C3b by gel filtration on Seph-
arose CL-2B in PBS (Pharmacia LKB Biotechnology, Piscataway,staining. The specific activity of the C1q was 400 hemolytic units
NJ), and the expected Mr was confirmed by SDS±PAGE. Peak frac-(Z) per mg of protein using the assay based on the BioRex drop
tions were pooled, aliquoted, and stored at 2808C.through fraction of human serum (Tenner et al., 1981b). Protein
was assayed by the micro BCA (bicinchoninic acid method; Pierce
Preparation of K562 Cells with Cell Surface CR1Chemicals, Rockville, IL), and C1q concentrations were calculated
The plasmid pBSHyg, which directs the expression of hygromycinfrom a BSA standard curve.
resistance, was prepared by ligation of the 2.0 kb HindIII±NruI frag-The collagen domain of C1q was prepared from a pepsin digest
ment from REP3 (Groger et al., 1989) into the HindIII±HincII sites ofof C1q (Siegel and Schumaker, 1983) and purified by HPLC gel
Bluescript KS(2) (Stratagene, La Jolla, CA). The plasmid paABCDpermeation chromatography using the same TSK G4000SWXL, vide
directs the expression of the F allotype of human CR1 (Klicksteinsupra. Protein was quantified with the BCA assay, using BSA as a
et al., 1988). K562 cells were electroporated (250 V, 960 mF) withstandard.
200 ng of pBSHyg linearized with XmnI with or without 20 mg of
paABCD linearized with SfiI. Transfectants were selected by cultureBiotinylation of C1q
in RPMI with 20% FCS supplemented with hygromycin at 200 mg/In a typical biotinylation reaction, 840 mg of C1q was reacted with
ml for 2 weeks, then transferred to RPMI with 10% FCS. K562 cells4.3 mg of NHS-biotin (Pierce Chemicals, Rockville, IL) in 1 ml of
transfected with pBSHyg alone were termed K-Hyg, and thosePBS for 30 min at room temperature with intermittent agitation. The
transfected with paABCD were termed K-CR1. The K-CR1 cells werereaction was stopped by the addition of concentrated ethanolamine
immunopanned (Wysocki et al., 1978) on immobilized anti-CR1 MAbto give a final concentration 0.1 M. The reaction mixture containing
(YZ-1) (Changelian et al., 1985) to select a uniformly positive popula-
C1qbio was subsequently dialyzed against 120 mM KCL, 10 mM Tris/
tion of cells. The CR1 expression on the control K-Hyg and K-CR1
HCl (pH 7.4) and the protein assayed. We were not able to determine transfectants was assessed by YZ-1 and FACs analysis, vide infra.
the final biotin:C1q ratio using the reagents provided with the bio- Once during the period of experimentation, the K-CR1 transfectants
tinylation kit, but it was necessary to biotinylate ªlightlyº to avoid were reselected by panning using YZ-1 to enhance CR1 expression.
aggregation. Each batch of C1qbio was tested for functional activity Western blotting of transfected cells to detect CR1 was performed
(Tenner et al., 1981b). as described (Yoon and Fearon, 1985). For the adhesion assay,
(C3b)2 was adsorbed to plastic wells in 50 mM Tris buffer (pH 9),
Radioiodinated C1q and C1q Collagen Tails and the plate was blocked with 1% BSA. K562 transfectants were
Glucose oxidase (Sigma) and lactoperoxidase (Sigma) were sepa- added and allowed to bind for 30 min at room temperature. After
rately coupled to beads of cross-linked bis-acrylamide/azlactone gently washing the plates, the adherent cells were enumerated using
copolymer beads (3M Emphaze; Pierce Chemicals, Rockville, IL) light microscopy.
according to the manufacturer's instructions. For both enzymes,
the coupling ratio was 1 mg of protein per hydrated equivalent of FACS Analysis
24 mg of dried beads. The optimal ratio (1/4) of coupled glucose A FACStar (Becton Dickinson, San Jose, CA) was used, and 104 cells
wereanalyzed for each variable. Transfected cells were assessed foroxidase to coupled lactoperoxidase was determined in a preliminary
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CR1 expression using the murine MAb YZ-l and FITC-goat anti- [pH 4.8] buffer 3 50 ml at a flow of 5 ml/ min) was coupled to a
CM5 sensor chip (Pharmacia) using EDC and NHS according to themouse IgG (Tago-Biosource, Camarillo, CA).
manufacturer's instructions (Johnsson et al., 1991). These condi-
tions resulted in 8852±9150 RU stably coupled in five separate im-125I-C1q Binding to Transfected Cells
mobilizations. Binding studies were performed in PBS at 258C usingBinding was performed in a polypropylene microfuge tube using
a flow rate of 5 ml/min. For analysis of (C3b)2 binding, the immobilizedªHBSS/2º (HBSS without Ca11 and Mg11), which was diluted with
rsCR1 was regenerated for subsequent analysis by washing withan equal volume of 5% glucose-0.2% gelatin solution. The total
0.1 M sodium citrate (pH 5.0). In C1q binding studies, the CR1 wasreaction volume of 0.33 or 0.44 ml contained 5 3 106 cells/ml and
regenerated by washing with 0.5 M NaCl. Data was analyzed usingincreasing amounts of 125I-C1q (specific activity: 1.1 3 106 cpm/ mg).
BIAcore Incorporated software (BIA Evaluation and BIA Simulation,The binding reaction proceeded at room temperature for 45 min
Pharmacia).with regular agitation. Aliquots (0.1 ml) of the reaction mixture were
removed and layered onto 300 ml of an oil mixture (85% dibutyl
phthalate, 15% dinonyl phthalate) in microfuge tubes (0.4 ml of Acknowledgments
polyethylene, #1404±1000, USA/Scientific Plastics, Ocala, FL). The
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